MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer

This study is testing an MRI-guided ultrasound ablation procedure — using focused sound waves to destroy cancer tissue — as a treatment for low to intermediate risk prostate cancer. The procedure is guided by real-time MRI imaging to precisely target only the cancerous tissue while sparing surrounding healthy tissue. **You may be eligible if:** - You are male, between 45 and 80 years old - You have biopsy-confirmed prostate cancer of low to intermediate risk (Gleason grade group 1, 2, or 3) - Your cancer has not spread beyond the prostate (stage T2c or lower) - Your PSA level is 20 ng/mL or less - You have not yet had any treatment for prostate cancer - Your life expectancy is more than 10 years **You may NOT be eligible if:** - You have already received treatment for prostate cancer - Your cancer is high-risk or has spread beyond the prostate - Your PSA is above 20 ng/mL - You do not meet the biopsy criteria specified in the study Talk to your doctor to see if this trial is right for you.